Annual Dialysis Conference Annual Meeting Coverage

Annual Dialysis Conference

Cinacalcet May Reduce ESA Use

PHOENIX—Cinacalcet hydrochloride (CH) treatment in dialysis patients with secondary hyperparathyroidism may improve responsiveness to an erythropoiesis-stimulating agent (ESA) by reducing systemic inflammation, resulting in decreased ESA requirements, new data suggest.

Next post in Annual Dialysis Conference